Table 4.
Regression modeling results for exercise measurements, stratified by serum brain natriuretic peptide (BNP), presented as coefficient, 95% confidence interval (CI), and p value
BNP ≥ 100 pg/ml (n = 12) | BNP < 100 pg/ml (n = 16) | ||||||
---|---|---|---|---|---|---|---|
Coefficient | 95% CI | p | Coefficient | 95% CI | p | p* | |
Measurements at peak exercise | |||||||
Oxygen consumption, ml/kg/min | 0.50 | (−1.38, 2.38) | 0.60 | −0.98 | (−2.60, 0.65) | 0.23 | 0.24 |
Heart rate, beats/min | −2.17 | (−5.62, 1.29) | 0.22 | −1.46 | (−4.46, 1.54) | 0.34 | 0.76 |
Respiratory rate, breaths/min | −1.24 | (−2.76, 0.28) | 0.11 | −2.76 | (−4.04, −1.48) | < 0.01 | 0.13 |
Minute ventilation, L/min | −3.15 | (−6.77, 0.47) | 0.09 | −5.74 | (−8.86, −2.61) | < 0.01 | 0.28 |
Oxygen saturation, % | 0.51 | (−0.29, 1.32) | 0.21 | 0.41 | (−0.28, 1.10) | 0.25 | 0.84 |
Measurements at anaerobic threshold | |||||||
Oxygen consumption, ml/kg/min | 1.85 | (0.59, 3.12) | < 0.01 | 0.68 | (−0.39, 1.75) | 0.21 | 0.14 |
Respiratory rate, breaths/min | −1.26 | (−3.22, 0.69) | 0.20 | −2.37 | (−4.11, −0.62) | 0.01 | 0.39 |
Minute ventilation, L/min | 0.49 | (−1.37, 2.34) | 0.60 | −0.94 | (−2.57, 0.69) | 0.25 | 0.24 |
VE/VCO2 | −2.40 | (−3.69, −1.12) | < 0.01 | −1.43 | (−2.67, −0.19) | 0.02 | 0.27 |
Each regression coefficient corresponds to difference in average post-phase outcome between sildenafil and placebo, adjusted for pre-phase values, study period, and treatment sequence. VE/VCO2: ventilatory equivalents of carbon dioxide.
p-value from test of interaction evaluating whether the treatment difference is equal in the two BNP strata.